[Advances treatment of osteoporosis: new molecules, new strategies]. / Avancées thérapeutiques: nouvelles molécules, nouvelles stratégies.
Bull Acad Natl Med
; 194(8): 1505-16; discussion 1516-8, 2010 Nov.
Article
em Fr
| MEDLINE
| ID: mdl-22046713
ABSTRACT
Practitioners already have a wide range of effective drugs for the treatment of osteoporosis, but new options are needed to prevent fractures in patients with this chronic and disabling disease. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss, based on inhibition of bone resorption by osteoclasts (anti-RANK ligand antibodies and cathepsin K inhibitors) or stimulation of bone formation by osteoblasts (anti-sclerostin antibodies). These future treatments (anti-RANK ligand antibodies should shortly be available) will add osteoporosis to the growing list of disorders amenable to targeted biotherapies.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Drogas em Investigação
/
Endocrinologia
/
Conservadores da Densidade Óssea
Limite:
Humans
Idioma:
Fr
Revista:
Bull Acad Natl Med
Ano de publicação:
2010
Tipo de documento:
Article